Organization profile

Organization profile

Molecular profiling of cancer (MPC) is an interdisciplinary,state-of-the-art form of precision medicine (PM) that has produced considerable advances in the ability to treat patients with a variety of cancers. MPC enables personalization of treatment through the selection of effective targeted therapies and avoidance of unnecessary chemotherapy. These qualities minimize chemo-related adverse effects, increase quality of life, and reduce the length of hospitalizations and costs of patient care. Because the science of MPC is relatively new, the majority of possible MPC tests (covering the entire spectrum of diseases and treatments) are yet to be discovered, offering immense opportunities for research and care improvements using MPC. The current state of the art in MPC-based PM has hit a performance ceiling that still places an unacceptable number of patients in a “grey zone” of indeterminate biologic/outcome stratification which precludes selection of optimal treatment plans for these patients. Our Grand Challenge is to build on a foundation of prior accomplishments by our team, (including the creation of the only precision test for ovarian cancer treatment in existence that is accurate enough to be clinically actionable), leveraging the UMN scientific environment, as well as a network of external scientists with who we have a track record of productive collaboration, to develop a leading-edge PM program focused on single cell analytics.

This program will enable the scalable creation of optimal therapy selection tests, with an accuracy that vastly exceeds the present generation of such tests, thus conferring the advantages of PM to patients that currently cannot be helped by conventional MPC tests. The overall driving theme of the projec's objectives is a signifiant improvement in outcomes of cancer patients via transformative advances in the way personalized molecular profiles are created.


Grand Challenges Research Awards: Phase 3


Project: Grand Challenges